Loading
companiesCompany
Bulsara Bioworks
Bulsara Bioworks is a 2025 start-up focused on precise p53-pathway activation for solid tumours.
Overview
Bulsara Bioworks is a San Francisco start-up founded in 2025 and backed by Even One Ventures, focused on precise activation of the p53 pathway in solid tumours. The company describes a focused drug-development model built around p53 pathway biology, its work is preclinical, and it exhibited at BIO 2026. OnCo links it to TP53 as a target and to the p53, RB and cell-cycle checkpoint pathway. Whether the p53 pathway, long considered undruggable, can be reactivated selectively in tumour cells is the question its programme depends on, and no clinical data yet exist. The TP53 target page carries the history of earlier attempts.
Similar pages
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares p53 / RB / cell-cycle checkpoint, TP53.
- CompanyFinalDose
Shares TP53 and the tag early-stage.
- IdeaExtend p53 reactivation beyond the Y220C mutation
Shares p53 / RB / cell-cycle checkpoint, TP53.
- TreatmentEprenetapopt
Shares p53 / RB / cell-cycle checkpoint, TP53.
- IdeaMilestone prizes for first-in-class mechanisms reaching human proof of concept
Shares p53 / RB / cell-cycle checkpoint, TP53.
- Key paperEl-Deiry 1993: WAF1, the gene through which p53 stops cell division
Shares p53 / RB / cell-cycle checkpoint, TP53.
- Key paperAssociation of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma
Shares p53 / RB / cell-cycle checkpoint, TP53.
- Key paperGenomic correlates of clinical outcome in advanced prostate cancer
Shares p53 / RB / cell-cycle checkpoint, TP53.